mRNA Platform Market to grow with a CAGR of 35.20%
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global mRNA Platform Market.
According
to TechSci Research report, “Global mRNA Platform Market Industry Size,
Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global mRNA Platform Market
has valued at USD 7.30 billion in 2022 and is anticipated to witness an
impressive growth in the forecast period with a CAGR of 35.20% through 2028. This can be due to collaborations and
partnerships among leading companies with a diverse approach to merge the
expertise of individual companies and to strengthen their position in the
market.
The
speed of development is a significant driver of demand in the global mRNA
(messenger RNA) platform market. The mRNA platform's ability to accelerate the
development of vaccines, therapies, and other medical products has been a
game-changer in biotechnology and healthcare. One of the most prominent
examples of the speed of development in the mRNA platform market is the
development of COVID-19 vaccines. mRNA vaccine candidates for COVID-19 were
developed, tested, and authorized for emergency use in record time, often
within a matter of months. This speed was crucial in responding to a global
pandemic. The mRNA platform's flexibility allows for rapid adaptation to
emerging infectious pathogens and new variants. This is especially important in
addressing evolving public health threats. mRNA technology can be customized
quickly to target specific diseases or conditions. This customization enables
researchers and companies to respond rapidly to emerging healthcare challenges.
The speed of mRNA vaccine and therapy development has been facilitated by
expedited clinical trial processes during public health emergencies. Regulatory
agencies, such as the FDA, have worked closely with developers to streamline
the approval process.
Beyond
COVID-19, mRNA technology was being explored for a wide range of infectious
diseases, including influenza, HIV, and Zika virus. mRNA vaccines have the
advantage of rapid development and adaptation to new variants. Companies
working in the mRNA platform market were expanding their operations globally to
reach wider markets. This included collaborations with international partners
and establishing manufacturing facilities in different regions.
Browse over XX market data Figures and spread through 110 Pages and an
in-depth TOC on " mRNA Platform Market.”
In
April 2023, the inaugural face-to-face conference of the mRNA Technology
Transfer Program, hosted by WHO Director-General Tedros Adhanom Ghebreyesus,
drew more than 200 delegates to Cape Town (South Africa). The mRNA technology
hub facility at Afrigen Biologics and Vaccines (henceforth Afrigen; Cape Town,
South Africa) was also inaugurated this past week. The scheme, which was
introduced in 2021 as a reaction to the unequal access to the COVID-19 vaccine
globally, is a partnership between WHO, Medicines Patent Pool, and corporate
and public partners from 15 LMICs in Africa, Asia, Europe, and South America.
Its goal was to provide LMICs the ability to independently design, produce, and
distribute mRNA vaccines. Afrigen, one
of the partners, oversees the study, development, and transfer of mRNA vaccine
platforms, with the South African Medical Research Council serving as
sustainability coordinator. The pharmaceutical business Biovac (Cape Town,
South Africa) will get the technology first before it is distributed to
partners on other continents. Biovac will escalate manufacturing and
distribution of the goods throughout the African partner countries.
Storage and distribution present significant
challenges in the global mRNA platform market, particularly for mRNA-based
vaccines and therapies. These challenges are influenced by several factors
related to the nature of mRNA molecules and the need to maintain their
stability and integrity. mRNA molecules, especially those used in mRNA vaccines
and therapies, are highly sensitive to temperature fluctuations. Maintaining
the integrity of mRNA requires strict temperature control to prevent
degradation. Some mRNA vaccines, such as the COVID-19 vaccines developed by
Pfizer-BioNTech and Moderna, require storage at ultra-low temperatures
(typically around -70°C or colder) to remain stable. This necessitates
specialized storage and transportation infrastructure. Maintaining the cold
chain, which is the temperature-controlled supply chain, for mRNA-based
products is complex and costly. Ensuring that vaccines and therapies remain
within the recommended temperature range from manufacturing to administration
is challenging, especially in resource-limited regions.
Global mRNA Platform Market segmentation is based on Indication, Usability, mRNA Type, End User and Region. Based on mRNA Type, Global MRNA Platform Market is segmented into Nucleoside-Modified
mRNA, Self-Amplifying mRNA, Unmodified mRNA. Nucleoside-modified mRNA,
often referred to simply as modified mRNA, is a form of synthetic RNA
(ribonucleic acid) that has been engineered and chemically modified to enhance
its stability, translational efficiency, and safety when used in various
applications, particularly in the field of biotechnology and medicine. These
modifications involve changes to the basic building blocks of mRNA, which are
nucleosides. Nucleoside-modified mRNA is created by chemically modifying the
individual nucleosides that make up the mRNA molecule. These modifications are
carefully designed to improve the mRNA's properties for specific applications.
Modifications make mRNA more stable, reducing its susceptibility to degradation
by cellular enzymes and increasing its shelf life during storage and
transportation.
Based on Region, North America dominated the Global mRNA Platform Market.
The United States has a large and lucrative healthcare market with a
well-developed infrastructure. The availability of funding, healthcare
facilities, and a high demand for innovative therapies has encouraged companies
to focus their efforts on North America. North America was an early adopter of
mRNA technology, which gained significant attention and investment before it
gained global prominence. This head start allowed North American companies to
establish themselves as leaders in the field. North American companies have
well-established global distribution networks, allowing them to distribute mRNA
vaccines and therapies efficiently to different parts of the world.
Asia-pacific region to fastest growth in
the Global mRNA Platform Market. The Asia-Pacific region is home to a large and
diverse population, including some of the world's most populous countries such
as China and India. This demographic diversity presents a substantial market
for vaccines, therapies, and other mRNA-based medical products. Many countries
in the Asia-Pacific region were increasing their investments in healthcare
infrastructure and research and development. This investment created an environment
conducive to the development and adoption of innovative medical technologies
like mRNA therapies and vaccines. The region's history of emerging infectious
diseases, such as SARS and MERS, highlighted the need for advanced vaccine
technologies. mRNA vaccines, known for their rapid development capabilities,
were seen as valuable tools for responding to future outbreaks.
Some
of the major companies operating in the Global
mRNA Platform Market include:
- AstraZeneca
PLC
- Asuragen,
Inc.
- Catalent
Pharma Solutions
- Arcturus
Therapeutics, Inc.
- BioNTech
AG
- CRISPR
Therapeutics Inc.
- AKESOgen,
Inc.
- baseclick
GmbH
- Accent
Therapeutics Inc.
- Accanis
Biotech F&E GmbH & Co KG
Download Free Sample Report
Customers can also request
10% free customization on this report.
“Certain areas, particularly in
North America, are projected to exert significant demand for mRNA Platform. The
growth in the competitive landscape and the presence of well-established
companies in the market, committed to enhance the overall wellbeing of people each
year, are expected to contribute to a remarkable growth of the Global mRNA
Platform Market in the forecast period," said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based Global management consulting
firm.
mRNA
Platform Market – Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2018-2028 Segmented
by Indication (Autoimmune Diseases, Cancer,
Infectious Diseases, Rare Diseases,
Respiratory Diseases), by Usability
(Prophylactic Vaccines, Therapeutic Drugs, Therapeutic Vaccines), by mRNA Type
(Nucleoside-Modified mRNA, Self-Amplifying
mRNA, Unmodified mRNA), by End User (Hospitals & Clinics, Pharmaceutical
Companies, Research
Organization), by region, and Competition evaluated the future
growth potential of Global mRNA Platform Market and provides statistics &
information on market size, structure, and future market growth. The report
intends to provide innovative market intelligence and help decision makers take
sound investment decisions. Besides, the report also identifies and analyzes
the emerging trends along with essential drivers, challenges, and opportunities
in Global mRNA Platform Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com